Steve Lenier

Steve Lenier

Contributing Writer

Steve Lenier began a career in medical literature over 30 years ago. He has worked on a variety of publications and projects, and across a number of specialties. Since 2005 most of his time has been spent covering ophthalmology, both print and online.

  • All
  • Deals
  • Devices and Diagnostics
  • Digital
  • Genetics
  • Pharma
Will Dexycu’s Cost Inhibit Its Use?

Will Dexycu’s Cost Inhibit Its Use?

Eric Donnenfeld, MD, of Ophthalmic Consultants of Long Island, recently performed the first cataract surgery in the country using Dexycu (EyePoint Pharmaceuticals), administered as a ...
Read More
‘Shark Tank’-like Winning Pitch Challenge Beckons Innovative Ideas by February 18

‘Shark Tank’-like Winning Pitch Challenge Beckons Innovative Ideas by February 18

A new Winning Pitch Challenge (WPC) symposium is coming to the 2019 American Society of Cataract and Refractive Surgery meeting, providing an opportunity for entrepreneurs ...
Read More
Nicox Patiently Pursues Moves to Build Value

Nicox Patiently Pursues Moves to Build Value

Nicox SA has taken several steps in the past few months to increase shareholder value. It has two product candidates headed toward Phase II trials, ...
Read More
Will Changes in the FDA’s 510(k) Process Be Good for Innovators?

Will Changes in the FDA’s 510(k) Process Be Good for Innovators?

Key players in the medical device industry, including one major player in ophthalmology, have issued mixed reviews in response to the Food and Drug Administration’s ...
Read More
Lessons and Pearls for Moving the Dry Eye Space Forward

Lessons and Pearls for Moving the Dry Eye Space Forward

Before he was chairman of Oyster Point Pharmaceuticals, Michael Ackermann, PhD, worked with a team developing an implantable device. It looked promising, but it was ...
Read More
Explaining the Explosion in the Dry Eye Space

Explaining the Explosion in the Dry Eye Space

At OIS@AAO 2018, strong attendance at the breakfast breakout session “Evolution of the Dry Eye Market” made a statement about the current level of interest ...
Read More
The Gems You’ll Find at OIS@AAO 2018

The Gems You’ll Find at OIS@AAO 2018

Diamonds are emerging as the new 10th anniversary gift. Here’s a look at a few of gems you can mine at the 10th OIS@AAO in ...
Read More
Alcon-TrueVision Partnership Delivers on Heads-Up Surgery

Alcon-TrueVision Partnership Delivers on Heads-Up Surgery

At OIS@ASRS 2016, Forrest Fleming, then CEO of TrueVision Systems, announced a new partnership with Alcon. He also introduced the result of that pairing: the ...
Read More
Gene Therapy Treatments Are Filling Some Companies’ Pipelines

Gene Therapy Treatments Are Filling Some Companies’ Pipelines

Major pharma companies in ophthalmology aren’t the only ones making plays in the gene therapy space, as we reported last week. Mid-size and small companies ...
Read More
Big Companies Keep Making Big Plays in Gene Therapy

Big Companies Keep Making Big Plays in Gene Therapy

When Allergan and Editas Medicine disclosed this week that they would move forward on their collaboration to develop a genome editing-medicine for treatment of an ...
Read More
Ocular Therapeutix Revamps to Address FDA’s Dextenza Concerns

Ocular Therapeutix Revamps to Address FDA’s Dextenza Concerns

When Ocular Therapeutix resubmitted its new drug application for Dextenza late in June, it represented a milestone in the company’s effort to essentially reshape itself ...
Read More
A String of Pearls for Navigating the FDA

A String of Pearls for Navigating the FDA

WASHINGTON, DC - Having OIS@ASCRS 2018 here provided the perfect opportunity for representatives of the US Food and Drug Administration to impart wisdom on how ...
Read More